Antimicrobial resistance of
Helicobacter pylori
antibiotic
belgium
prevalence
resistance
Journal
Acta clinica Belgica
ISSN: 2295-3337
Titre abrégé: Acta Clin Belg
Pays: England
ID NLM: 0370306
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
pubmed:
28
1
2021
medline:
9
3
2022
entrez:
27
1
2021
Statut:
ppublish
Résumé
Data on An observational cross-sectional study was performed in the province of West Flanders, Belgium for collecting gastric biopsies to examine the resistance of HP. The study population consisted of patients who underwent a gastroduodenoscopy for any medically indicated purpose. Rapid urease testing (RUT) was performed on all biopsies and cultures were only started if the RUT showed positive. 512 patients participated of whom 495 were eligible for analysis: 438 in first line testing and 57 in second line. The growth of HP was successful in 88.9% (n = 88/99) of which 52.3% (n = 46/88) resulted in an antibiogram. The resistance rate in first line was based on 37 succeeded antibiograms and showed 13.5% resistance for clarithromycin (95% confidence interval; 2.5% to 24.5%); 29.7% for metronidazole; 29.7% for levofloxacin; 11.4% for rifampicin; 2.7% for amoxicillin and 0% for tetracycline. The primary clarithromycin resistance rate of HP could still be slightly under 15% in West Flanders, Belgium. This might implicate a clarithromycin-based triple therapy is an option for first line empiric eradication in this region according to the Maastricht V/Florence consensus although conclusions must be interpreted with caution due to the rather small sample size. Further testing in Flanders is recommended to confirm these results.
Identifiants
pubmed: 33502281
doi: 10.1080/17843286.2021.1872307
doi:
Substances chimiques
Anti-Bacterial Agents
0
Levofloxacin
6GNT3Y5LMF
Clarithromycin
H1250JIK0A
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM